Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pharmacological Countermeasures for High Altitude

Augmentation of Medical Readiness and Physical Performance at High Altitude Using Pharmacological Countermeasures

The aim of this randomized, double-blind study is to determine whether erythropoietin (Procrit) and acetazolamide: 1) mitigates altitude-induced decrements in performance at moderate altitude (3,000 m) and 2) mitigates altitude-induced decrements in performance and reduce acute mountain sickness during prolonged exposure to high altitude (4,300 m; 15 days). Volunteers will complete 5 study phases: Phase 1) sea level baseline testing and a moderate altitude exposure; Phase 2) 4 week study intervention - randomly assigned to receive erythropoietin or placebo); Phase 3) 3 1/2 days of acetazolamide and a moderate altitude exposure; Phase 4) high altitude acclimatization - 15 days at Pikes Peak; and Phase 5) two week deacclimatization. Test battery include VO2peak, 3.2 km treadmill time trial, measures of gas exchange and ventilation during rest and exercise, and blood collection.

Studieöversikt

Status

Rekrytering

Betingelser

Detaljerad beskrivning

This study will use a double-blind randomized study design in which one group will receive erythropoietin and the other a placebo (saline) for 4 weeks, then both groups will receive acetazolamide. Eighteen men and women volunteers will complete 5 study phases: Phase 1) two week sea level baseline testing (orientation, two VO2peak assessments, three 3.2 km treadmill time-trial, assessment of resting ventilation, venipuncture and capillary blood collection, and Hbmass assessment), and a VO2peak and 3.2 km treadmill time-trial moderate altitude (3,000 m); Phase 2) 4 week intervention to receive subcutaneously erythropoietin or placebo. The erythropoietin (Procrit) dosing regimen will consist of 50 IU/kg three times a week (M-W-F); Phase 3) a second moderate altitude exposure (VO2peak and 3.2 km treadmill time-trial with acetazolamide administered (orally; 250 mg b.i.d) for 3 1/2 nights starting the day before the altitude exposure; Phase 4) high altitude acclimatization in which volunteers will reside for 15 days at 4,300 m altitude (Pikes Peak, Colorado Springs) completing multiple VO2peak assessments and 3.2 km treadmill time-trials, resting ventilation, venipuncture and capillary blood collection; and Phase 5) deacclimatization phase to assess changes in hematological biomarkers after returning from Pikes Peak. This study consists of 41 visits over a ~10 week time period. Visits will take place in Natick, MA and the Pikes Peak High Altitude Research Laboratory at Colorado Springs. Additional assessments that will be completed multiple times during the study include: acute mountain sickness questionnaire, lung gas diffusion at rest and during exercise, oxygen saturation, arterialized blood gases (PO2, PCO2, pH, HCO3) and heart rate during rest, exercise, and sleep, and muscle tissue oxygenation. The primary outcome is 3.2 km treadmill time-trial performance. Secondary outcomes include: incidence and severity of acute mountain sickness, ventilation and gas exchange, Hbmass, Hb concentration, Hct, arterialized blood gases, lung diffusion at rest and during exercise, oxygen saturation and heart rate during rest, exercise, and sleep.

Studietyp

Interventionell

Inskrivning (Förväntat)

18

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 40 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Age 18-40 years
  • In good health as determined by the Office of Medical Support & Oversight (OMSO) General Medical Clearance
  • Runs at least 3 times per week and able to complete a two mile run in ≤ 21 minutes (Civilian Volunteers) or passed his/her most recent Army Combat Fitness Test (ACFT) (Military Volunteers Only)
  • Willing to not exercise, or drink alcoholic and/or caffeinated beverages 24 hours prior to each testing session or the acute altitude exposure to 3,000 m
  • Abstain from alcoholic beverages during the 15 day residence at the summit of Pikes Peak
  • Abstain from drinking alcohol or caffeine at least 24 hours before a testing session during Phases 1 and 3
  • Willing to stay and exercise in an altitude chamber (the size of a dorm room) for ~2.5 hours
  • Wiling to reside at the summit of Pikes Peak (4,300 m altitude) and share dormitory area (bunk area, shower, and bathroom), potentially with people of the opposite sex for 15 days
  • Up to date on COVID-19 vaccination

Exclusion Criteria:

  • Women who are pregnant or planning to become pregnant during the study
  • Taking prescription medication, or over-the-counter medications other than contraceptives, unless approved by OMSO & PI
  • Born at altitudes greater than 2,100 m (7,000 ft)
  • Living in areas that are more than 1,200 m (4,000 ft) or have traveled to areas that are more than 1,200 m for five days or more within the last 2 months
  • Prior diagnosis of High Altitude Pulmonary Edema (HAPE) or High Altitude Cerebral Edema (HACE)
  • Musculoskeletal injuries that compromise the ability to walk/run on a treadmill or hike steep terrain
  • Abnormal blood count in accordance with OMSO - Normal Hb men: 12.6-17.7 g·dL-1 and women: 11.1-15.9 g·dL-1 or Normal Hct men: 37.5-48% and women: 34.0-45%, or presence of abnormal blood chemicals (hemoglobin S or Sickle Cell Trait)
  • Any history of malignancy
  • Personal or family history of blood clots
  • Abnormal prothrombin time/partial thromboplastin time (PT/PTT) test or problems with blood clotting
  • History of thromboembolic disease, hypertension, and known risk factors of cardiovascular disease
  • Blood donation within 8 weeks of beginning the study
  • History of seizures
  • History of inflammatory bowel disease
  • Any recent (within 4-6 weeks) and or expected history of prolonged periods of immobility or limited activity (including recent or upcoming surgery)
  • No evidence of iron deficiency (ferritin < 45 ng/ml)
  • Smokers or tobacco/nicotine (unless quit > 1 month prior to study orientation)
  • History of asthma
  • Experience recent (< 1 month of starting the study) cold, coughs, or respiratory tract infections
  • Allergy to skin adhesive
  • Known allergy to sulfa drugs
  • Evidence of apnea or sleeping disorder
  • Present condition of alcoholism, use of anabolic steroids, other substance abuse issues
  • Inability to tolerate iron supplement

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Acetazolamide
Acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
Carbonic Anhydrase Inhibitor
Andra namn:
  • Diamox
Experimentell: Erythropoietin and Acetazolamide
Erythropoietin (subcutaneously) 50 IU /kg three times a week for 4 weeks. After the 4 week Erythropoietin, acetazolamide (orally) 250 mg twice a day for 3 1/2 days.
Carbonic Anhydrase Inhibitor
Andra namn:
  • Diamox
Hormone for red blood cell
Andra namn:
  • Procrit

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
3.2 km self-paced treadmill time trial performance
Tidsram: 35 minutes
Time to complete self-paced 3.2 km treadmill time trial (min:sec)
35 minutes

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
VO2peak
Tidsram: 30 minutes
Peak aerobic capacity will be assessed using a metabolic cart.
30 minutes
Lake Louise Acute Mountain Sickness Score
Tidsram: 10 minutes
Acute mountain sickness and severity will be assessed using the Lake Louise acute mountain sickness questionnaire. This Likert scale assess acute mountain sickness with scores ranging from 0 to 12. Zero indicates no acute mountain sickness and 12 indicates severe acute mountain sickness.
10 minutes
Ventilation rate
Tidsram: 20 minutes
Ventilation rate will be assessed using a pneumotachometer.
20 minutes
Percent body fat
Tidsram: 10 minutes
Percent body fat will be assessed using Dual Energy X-ray Absorptiometry.
10 minutes
Oxygen Saturation
Tidsram: 35 minutes
Oxygen saturation will be assessed using a finger pulse oximeter.
35 minutes
Erythropoietin
Tidsram: 4 hours
Erythropoietin will be assessed using an ELISA.
4 hours
Hematocrit
Tidsram: 5 minutes
Hematocrit will be assessed using manual hematocrit method.
5 minutes
Reticulocyte
Tidsram: 2 hours
Reticulocyte will be assessed using a hematology analyzer.
2 hours
Ferritin
Tidsram: 2 hours
Ferritin will be assessed using an ELISA.
2 hours
C-reactive protein
Tidsram: 2 hours
C-reactive protein will be assessed using an ELISA.
2 hours
Soluble transferrin
Tidsram: 2 hours
Soluble transferrin will be assessed using an ELISA.
2 hours
Arterialized capillary PO2
Tidsram: 5 minutes
Arterialized capillary PO2 will be assessed using a blood gas analyzer.
5 minutes
Arterialized capillary PCO2
Tidsram: 5 minutes
Arterialized capillary PCO2 will be assessed using a blood gas analyzer.
5 minutes
Arterialized capillary pH
Tidsram: 5 minutes
Arterialized capillary pH will be assessed using a blood gas analyzer.
5 minutes
Hbmass
Tidsram: 20 minutes
Hbmass will be assessed using the CO-rebreathing procedure.
20 minutes
Muscle tissue oxygenation
Tidsram: 35 minutes
Muscle tissue oxygenation will be assessed using a non-invasive near-infrared spectroscopy.
35 minutes
Lung Diffusion of carbon monoxide
Tidsram: 35 minutes
Lung Diffusion of carbon monoxide will be assessed using a spirometer.
35 minutes

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

27 maj 2022

Primärt slutförande (Förväntat)

30 augusti 2022

Avslutad studie (Förväntat)

30 augusti 2022

Studieregistreringsdatum

Först inskickad

17 mars 2022

Först inskickad som uppfyllde QC-kriterierna

28 mars 2022

Första postat (Faktisk)

29 mars 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 mars 2022

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 mars 2022

Senast verifierad

1 mars 2022

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Hypobar hypoxi

Kliniska prövningar på Acetazolamide

3
Prenumerera